# Phase IIB Clinical Trial of Hamsa-1™ in Metastatic Castration Resistant Prostate Cancer (CRPC)

> **NCT00684970** · PHASE2 · UNKNOWN · sponsor: **Tiltan Pharma Ltd.** · enrollment: 100 (estimated)

## Conditions studied

- Metastatic Castration Resistant Prostate Cancer (CRPC)

## Interventions

- **DRUG:** Hamsa-1™ TL-118

## Key facts

- **NCT ID:** NCT00684970
- **Lead sponsor:** Tiltan Pharma Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2009-03
- **Primary completion:** 2014-02
- **Final completion:** —
- **Target enrollment:** 100 (ESTIMATED)
- **Last updated:** 2013-12-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00684970

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00684970, "Phase IIB Clinical Trial of Hamsa-1™ in Metastatic Castration Resistant Prostate Cancer (CRPC)". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT00684970. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*